cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.16644703
title: Supplementary Material for: Comprehensive Analysis of Potential miRNA-Target mRNA-Immunocyte Subtype Network in Cerebral Infarction

description: <b><i>Introduction:</i></b> Cerebral infarction (CI) is one of the leading causes of serious long-term disability and mortality. <b><i>Objective:</i></b> We aimed to identify potential miRNAs and target mRNAs and assess the involvement of immunocyte infiltration in the process of CI. <b><i>Methods:</i></b> First, miRNA and mRNA data were downloaded from the Gene Expression Omnibus database, followed by differential expression analysis. Second, correlation analysis between differentially expressed mRNAs and differential immunocyte subtypes was performed through the CIBERSORT algorithm. Third, the regulatory network between miRNAs and immunocyte subtype-related mRNAs was constructed followed by the functional analysis of these target mRNAs. Fourth, correlation validation between differentially expressed mRNAs and differential immunocyte subtypes was performed in the GSE37587 dataset. Finally, the diagnostic ability of immunocyte subtype-related mRNAs was tested. <b><i>Results:</i></b> Up to 17 differentially expressed miRNAs and 3,267 differentially expressed mRNAs were identified, among which 310 differentially expressed mRNAs were significantly associated with immunocyte subtypes. Several miRNA-target mRNA-immunocyte subtype networks including hsa-miR-671-3p-ZC3HC1-neutrophils, hsa-miR-625-CD5-monocytes, hsa-miR-122-ACOX1/DUSP1/NEDD9-neutrophils, hsa-miR-455-5p-SLC24A4-monocytes, and hsa-miR-455-5p-SORL1-neutrophils were identified. LAT, ACOX1, DUSP1, NEDD9, ZC3HC1, BIN1, AKT1, DNMT1, SLC24A4, and SORL1 had a potential diagnostic value for CI. <b><i>Conclusions:</i></b> The network including miRNA, target mRNA, and immunocyte subtype may be novel regulators and diagnostic and therapeutic targets in CI.
DOI: 10.6084/m9.figshare.16644703.v1
title: Supplementary Material for: Comprehensive Analysis of Potential miRNA-Target mRNA-Immunocyte Subtype Network in Cerebral Infarction

description: <b><i>Introduction:</i></b> Cerebral infarction (CI) is one of the leading causes of serious long-term disability and mortality. <b><i>Objective:</i></b> We aimed to identify potential miRNAs and target mRNAs and assess the involvement of immunocyte infiltration in the process of CI. <b><i>Methods:</i></b> First, miRNA and mRNA data were downloaded from the Gene Expression Omnibus database, followed by differential expression analysis. Second, correlation analysis between differentially expressed mRNAs and differential immunocyte subtypes was performed through the CIBERSORT algorithm. Third, the regulatory network between miRNAs and immunocyte subtype-related mRNAs was constructed followed by the functional analysis of these target mRNAs. Fourth, correlation validation between differentially expressed mRNAs and differential immunocyte subtypes was performed in the GSE37587 dataset. Finally, the diagnostic ability of immunocyte subtype-related mRNAs was tested. <b><i>Results:</i></b> Up to 17 differentially expressed miRNAs and 3,267 differentially expressed mRNAs were identified, among which 310 differentially expressed mRNAs were significantly associated with immunocyte subtypes. Several miRNA-target mRNA-immunocyte subtype networks including hsa-miR-671-3p-ZC3HC1-neutrophils, hsa-miR-625-CD5-monocytes, hsa-miR-122-ACOX1/DUSP1/NEDD9-neutrophils, hsa-miR-455-5p-SLC24A4-monocytes, and hsa-miR-455-5p-SORL1-neutrophils were identified. LAT, ACOX1, DUSP1, NEDD9, ZC3HC1, BIN1, AKT1, DNMT1, SLC24A4, and SORL1 had a potential diagnostic value for CI. <b><i>Conclusions:</i></b> The network including miRNA, target mRNA, and immunocyte subtype may be novel regulators and diagnostic and therapeutic targets in CI.
DOI: 10.5281/zenodo.5517093
title: Supporting information of paper "Direct Laser Writing of Liquid Crystal Elastomers Oriented by a Horizontal Electric Field"

description: This dataset is the supporting material for the paper “Direct Laser Writing of Liquid Crystal Elastomers Oriented by a Horizontal Electric Field”, submitted for consideration and open review in Open Research Europe. In the follow the description of the file is reported: <strong>SIVideo_LCAlignment </strong>Video (.avi) [Supporting VideoZ1] showing the response of the unpolymerized mesogens to an electric field of 1.7 V/µm <strong>SIVideo_NailActuation</strong> Video (.avi) [Supporting VideoZ2] showing the thermally activated actuation of a LCE nail microstructure upon several rt-75 °C cycles. <strong>SIVideo_SimluationCube</strong> [Supporting VideoZ3] Video showing a simulation of the actuation of a LCE microcube upon heating. <strong>SIVideo_SimluationNail</strong> [Supporting VideoZ4] Video showing a simulation of the actuation of a LCE micronail upon heating. <strong>ImageZ1</strong> [Supporting Figure Z1]Simulation of the distribution of the electric field generated by flat electrode, view along the plane (cross section) with magnification of the central part of the working field. <strong>ImageZ2</strong> [Supporting Figure Z2] Photographs and thermal images of a LCE film obtained using a resin formulation identical to that employed in DLW on identical substrates that show the thermal response. Top: photograph of LCE films obtained by UV polymerization of a 7:3 LC-MA:LC-DA mixture over interdigitated flat ITO electrodes with an applied DC voltage. Upon heating with an infrared lamp (right column) the film bends and shortens. Middle: images acquired with a thermocamera highlighting the actuation temperature. Bottom: control LCE film polymerized as casted (without electric field). <strong>Simulations.zip </strong>Comsol (Version 5.6) source simulation files for LCE microcube and LCE micronail upon heating, and for the electric field electric generated by flat electrode in experimental conditions. Complete Report file in PDF is also available, containing all the parameters and equations used for simulation. Finally, the simulation results are provided as text .csv files.
DOI: 10.25917/8jdb-y324
title: Trap size measurements of Utricularia tubulata (Lentibulariaceae) from the Kimberley region of Western Australia.
DOI: 10.5517/ccdc.csd.cc1mwn8f
title: CCDC 1516125: Experimental Crystal Structure Determination

description: Related Article: Stephen P. Argent, Ivan da Silva, Alex Greenaway, Mathew Savage, Jack Humby, Andrew J. Davies, Harriott Nowell, William Lewis, Pascal Manuel, Chiu C. Tang, Alexander J. Blake, Michael W. George, Alexander V. Markevich, Elena Besley, Sihai Yang, Neil R. Champness, Martin Schröder|2020|Inorg.Chem.|59|15646|doi:10.1021/acs.inorgchem.0c01935
DOI: 10.5517/ccdc.csd.cc1mwnbh
title: CCDC 1516127: Experimental Crystal Structure Determination

description: Related Article: Stephen P. Argent, Ivan da Silva, Alex Greenaway, Mathew Savage, Jack Humby, Andrew J. Davies, Harriott Nowell, William Lewis, Pascal Manuel, Chiu C. Tang, Alexander J. Blake, Michael W. George, Alexander V. Markevich, Elena Besley, Sihai Yang, Neil R. Champness, Martin Schröder|2020|Inorg.Chem.|59|15646|doi:10.1021/acs.inorgchem.0c01935
DOI: 10.5517/ccdc.csd.cc1mwndk
title: CCDC 1516129: Experimental Crystal Structure Determination

description: Related Article: Stephen P. Argent, Ivan da Silva, Alex Greenaway, Mathew Savage, Jack Humby, Andrew J. Davies, Harriott Nowell, William Lewis, Pascal Manuel, Chiu C. Tang, Alexander J. Blake, Michael W. George, Alexander V. Markevich, Elena Besley, Sihai Yang, Neil R. Champness, Martin Schröder|2020|Inorg.Chem.|59|15646|doi:10.1021/acs.inorgchem.0c01935
DOI: 10.5517/ccdc.csd.cc28q9lx
title: CCDC 2106809: Experimental Crystal Structure Determination

description: Related Article: S. Xingfang, C. Changbao, Y. Zuhang, Y. Zhou|2011|Youji Huaxue|31|2052|
DOI: 10.5517/ccdc.csd.cc28qbx8
title: CCDC 2106850: Experimental Crystal Structure Determination

description: Related Article: W. Huang, G. Su, C. Pan, J. Qin, H. Tang, X. Yi|2011|Guangxi Shifan Daxue Xuebao Ziran Kexueban|29|1038|
DOI: 10.5281/zenodo.4721313
title: Dataset of Paper "High-performance low-cost solar collectors for water treatment fabricated with recycled materials, open-source hardware and 3d-printing technologies"

description: Dataset of Paper "High-performance low-cost solar collectors for water treatment fabricated with recycled materials, open-source hardware and 3d-printing technologies": Spectral reflectance of the studied materials Experimental results of the potassium ferrioxalate actinometry experiments for a commercial CPC reactor and the 3D printed CPC reactors coated with different reflective materials Experimental results of formaldehyde formation during the photocatalytic oxidation of methanol different test experiments. 10 years annualised cost of the studied reactors. Cost analysis of the 3D printed reactors. Control strategy of the solar tracking system.
DOI: 10.5281/zenodo.4721312
title: Dataset of Paper "High-performance low-cost solar collectors for water treatment fabricated with recycled materials, open-source hardware and 3d-printing technologies"

description: Dataset of Paper "High-performance low-cost solar collectors for water treatment fabricated with recycled materials, open-source hardware and 3d-printing technologies": Spectral reflectance of the studied materials Experimental results of the potassium ferrioxalate actinometry experiments for a commercial CPC reactor and the 3D printed CPC reactors coated with different reflective materials Experimental results of formaldehyde formation during the photocatalytic oxidation of methanol different test experiments. 10 years annualised cost of the studied reactors. Cost analysis of the 3D printed reactors. Control strategy of the solar tracking system.
DOI: 10.26106/qq4e-f210
title: Data to publication "Aerobic scope does matter in the temperature-size rule but only under optimal conditions" - concept
DOI: 10.5281/zenodo.4277904
title: Dataset: SODIS performance on the inactivation of E. coli under different irradiance and temperature conditions

description: SODIS performance on the inactivation of <em>E. coli</em> under different irradiance and temperature conditions. Experimental data for calibration of inactivation models. Description of Materials and Methods.
DOI: 10.5281/zenodo.4899573
title: Dataset of Paper "Solar Water Disinfection to Produce Safe Drinking Water. A Review of Parameters, Enhancements, and Modelling Approaches to Make SODIS Faster and Safer"

description: <strong>- </strong>Evolution of the spectral transmittance of polypropylene as a function of the accelerated ageing time.
DOI: 10.5281/zenodo.4899572
title: Dataset of Paper "Solar Water Disinfection to Produce Safe Drinking Water. A Review of Parameters, Enhancements, and Modelling Approaches to Make SODIS Faster and Safer"

description: <strong>- </strong>Evolution of the spectral transmittance of polypropylene as a function of the accelerated ageing time.
DOI: 10.5281/zenodo.5517159
title: Comparative genomics of eight aphid subfamilies reveals variable relationships between host horizontally-transferred genes and symbiont peptidoglycan metabolism.

description: Genome assemblies, annotations, and orthologs of aphids (<em>Geopemphigus sp.</em>, <em>Stegophylla sp.</em>, <em>Chaitophorus viminalis</em>, and<em> Pemphigus obesinymphae</em>) and their symbionts. step1_final_assemblies_and_annotations.tar.gz: Aphid genomes and annotations step2_protein_evidence_used_for_genome_annotation.tar.gz: Protein evidence used for aphid genome annotation step3_amino_acid_inputs_for_aphid_orthologs: amino acid inputs for aphid ortholog assignmentt step5_buchnera_genomes_and_annotations.tar.gz: Buchnera genomes and annotations
DOI: 10.5281/zenodo.5517156
title: Dataset from: A pragmatic benchmarking study of an evidence-based personalized approach in 1938 adolescents with high-risk idiopathic scoliosis

description: Dataset from a still non published study titled "A pragmatic benchmarking study of an evidence-based personalized approach in 1938 adolescents with high-risk idiopathic scoliosis"
DOI: 10.5281/zenodo.5517155
title: Dataset from: A pragmatic benchmarking study of an evidence-based personalized approach in 1938 adolescents with high-risk idiopathic scoliosis

description: Dataset from a still non published study titled "A pragmatic benchmarking study of an evidence-based personalized approach in 1938 adolescents with high-risk idiopathic scoliosis"
DOI: 10.6084/m9.figshare.16644820
title: Supplementary Material for: Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation

description: <b><i>Introduction:</i></b> Therapy of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with drugs such as ibrutinib and rituximab is often associated with immune suppression, opportunistic infections, and reactivation of virus infections such as hepatitis B virus (HBV). This risk is especially important in geographical regions like Asia where many potential therapy recipients have HBV infection. Also, whether safety and efficacy of ibrutinib in Asians and Europeans with advanced CLL/SLL are similar is unknown. We determined the safety and efficacy of ibrutinib compared with rituximab in advanced CLL/SLL including persons with HBV infection. We compared outcomes with data published from trials in persons of European descent. <b><i>Methods:</i></b> This is a post hoc analysis of a multicenter, phase-3 trial (NCT01973387). Subjects with advanced CLL/SLL were randomized 2:1 to receive ibrutinib, 420 mg/day, or rituximab, 500 mg/mE + 2, for 6 cycles. Subjects with resolved HBV infection were included. Endpoints were progression-free survival (PFS), overall response rate (ORR), survival, and adverse events including resolved HBV reactivation. <b><i>Results:</i></b> 131 subjects received ibrutinib (<i>N</i> = 87) or rituximab (<i>N</i> = 44) including 53 with resolved HBV infection. Median follow-up was 31 months (95% confidence interval: 28, 32 months). ORR was 61% (50, 71%) versus 7% (2, 18%; <i>p</i> &lt; 0.001). Median PFS was not reached in the ibrutinib cohort but must be &gt;40 months versus 8 months (7, 9 months; <i>p</i> &lt; 0.0001) in the rituximab cohort. Median survival was not reached but must be &gt;40 months versus 27 months (17 months, NE; <i>p</i> = 0.0006). In multivariable analyses, receiving ibrutinib increased PFS (hazard rate [HR] for failure = 0.12 [0.06, 0.23]; <i>p</i> &lt; 0.001) and decreased risk of death (HR = 0.31 [0.15, 0.63]; <i>p</i> &lt; 0.001). Median duration of exposure to ibrutinib was significantly longer than exposure to rituximab (28 vs. 5 months). The safety profile of ibrutinib was consistent with that observed in previous studies with no new safety signal. No subject receiving ibrutinib had HBV reactivation versus 2 receiving rituximab, despite much greater use of drugs to prevent HBV reactivation in the rituximab cohort. Outcomes were like those reported in persons of European descent, except ORR which, was unreliably correlated with PFS in Asians. <b><i>Conclusion:</i></b> Ibrutinib is safe and effective in persons with advanced CLL/SLL and better than rituximab in all therapy outcomes including risk of HBV reactivation. Outcomes with ibrutinib in Chinese were like those reported in persons of predominately European descent.
DOI: 10.6084/m9.figshare.16644820.v1
title: Supplementary Material for: Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation

description: <b><i>Introduction:</i></b> Therapy of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with drugs such as ibrutinib and rituximab is often associated with immune suppression, opportunistic infections, and reactivation of virus infections such as hepatitis B virus (HBV). This risk is especially important in geographical regions like Asia where many potential therapy recipients have HBV infection. Also, whether safety and efficacy of ibrutinib in Asians and Europeans with advanced CLL/SLL are similar is unknown. We determined the safety and efficacy of ibrutinib compared with rituximab in advanced CLL/SLL including persons with HBV infection. We compared outcomes with data published from trials in persons of European descent. <b><i>Methods:</i></b> This is a post hoc analysis of a multicenter, phase-3 trial (NCT01973387). Subjects with advanced CLL/SLL were randomized 2:1 to receive ibrutinib, 420 mg/day, or rituximab, 500 mg/mE + 2, for 6 cycles. Subjects with resolved HBV infection were included. Endpoints were progression-free survival (PFS), overall response rate (ORR), survival, and adverse events including resolved HBV reactivation. <b><i>Results:</i></b> 131 subjects received ibrutinib (<i>N</i> = 87) or rituximab (<i>N</i> = 44) including 53 with resolved HBV infection. Median follow-up was 31 months (95% confidence interval: 28, 32 months). ORR was 61% (50, 71%) versus 7% (2, 18%; <i>p</i> &lt; 0.001). Median PFS was not reached in the ibrutinib cohort but must be &gt;40 months versus 8 months (7, 9 months; <i>p</i> &lt; 0.0001) in the rituximab cohort. Median survival was not reached but must be &gt;40 months versus 27 months (17 months, NE; <i>p</i> = 0.0006). In multivariable analyses, receiving ibrutinib increased PFS (hazard rate [HR] for failure = 0.12 [0.06, 0.23]; <i>p</i> &lt; 0.001) and decreased risk of death (HR = 0.31 [0.15, 0.63]; <i>p</i> &lt; 0.001). Median duration of exposure to ibrutinib was significantly longer than exposure to rituximab (28 vs. 5 months). The safety profile of ibrutinib was consistent with that observed in previous studies with no new safety signal. No subject receiving ibrutinib had HBV reactivation versus 2 receiving rituximab, despite much greater use of drugs to prevent HBV reactivation in the rituximab cohort. Outcomes were like those reported in persons of European descent, except ORR which, was unreliably correlated with PFS in Asians. <b><i>Conclusion:</i></b> Ibrutinib is safe and effective in persons with advanced CLL/SLL and better than rituximab in all therapy outcomes including risk of HBV reactivation. Outcomes with ibrutinib in Chinese were like those reported in persons of predominately European descent.
DOI: 10.15161/oar.it/74107
title: CovidStat project data

description: This record contains the daily updated data of the CovidStat project. CovidStat is a project carried out by the CovidStat Working Group at INFN, whose creation was promoted within the Italian National Institute of Nuclear Physics with the aim of making a statistical analysis of the data provided daily by the Civil Protection on the spread of the pandemic in Italy. CovidStat data can interactively be browsed at https://covid19.infn.it.
description: The software to process this Root TTree is in the related identifier. Be sure to use the right corresponding version, based on the data in which Root TTree was generated.
DOI: 10.25917/gqb6-mm41
title: Voucher specimen image of Krueger 24 (Drosera margaritacea; Droseraceae).
DOI: 10.25917/7sq5-d232
title: Voucher specimen image of Krueger 25 (Drosera hartmeyerorum; Droseraceae).
DOI: 10.25917/txxp-ge36
title: Voucher specimen image of Krueger 26 (Utricularia gibba; Lentibulariaceae).
DOI: 10.5281/zenodo.5512613
title: Dataset related to article "Systematic review and meta-analysis of preclinical studies testing mesenchymal stromal cells for traumatic brain injury"

description: Mesenchymal stromal cells (MSCs) are widely used in preclinical models of traumatic brain injury (TBI). Results are promising in terms of neurological improvement but are hampered by wide variability in treatment responses. We made a systematic review and meta-analysis: 1) to assess the quality of evidence for MSC treatment in TBI rodent models; 2) to determine the effect size of MSCs on sensorimotor function, cognitive function and anatomical damage; 3) to identify MSC-related and protocol-related variables associated with greater efficacy; 4) to understand whether MSC manipulations boost therapeutic efficacy. The meta-analysis included 80 studies. After TBI, MSCs improved sensorimotor and cognitive deficits, and reduced anatomical damage. Stratified meta-analysis on sensorimotor outcome showed similar efficacy for different MSC sources and for syngeneic or xenogenic transplants. Efficacy was greater when MSCs were delivered in the first week post-injury, and when implanted directly into the lesion cavity. The greatest effect size was for cells embedded in matrices or for MSC-derivatives. MSC therapy is effective in preclinical TBI models, improving sensorimotor, cognitive and anatomical outcomes, with large effect sizes. These findings support clinical studies in TBI. The present dataset reports extrapolated data used for the meta-analysis
DOI: 10.5281/zenodo.5512612
title: Dataset related to article "Systematic review and meta-analysis of preclinical studies testing mesenchymal stromal cells for traumatic brain injury"

description: Mesenchymal stromal cells (MSCs) are widely used in preclinical models of traumatic brain injury (TBI). Results are promising in terms of neurological improvement but are hampered by wide variability in treatment responses. We made a systematic review and meta-analysis: 1) to assess the quality of evidence for MSC treatment in TBI rodent models; 2) to determine the effect size of MSCs on sensorimotor function, cognitive function and anatomical damage; 3) to identify MSC-related and protocol-related variables associated with greater efficacy; 4) to understand whether MSC manipulations boost therapeutic efficacy. The meta-analysis included 80 studies. After TBI, MSCs improved sensorimotor and cognitive deficits, and reduced anatomical damage. Stratified meta-analysis on sensorimotor outcome showed similar efficacy for different MSC sources and for syngeneic or xenogenic transplants. Efficacy was greater when MSCs were delivered in the first week post-injury, and when implanted directly into the lesion cavity. The greatest effect size was for cells embedded in matrices or for MSC-derivatives. MSC therapy is effective in preclinical TBI models, improving sensorimotor, cognitive and anatomical outcomes, with large effect sizes. These findings support clinical studies in TBI. The present dataset reports extrapolated data used for the meta-analysis